RESPIRI LIMITED (RSH)

The suspension of trading in the securities of Respiri Limited will be lifted immediately following the release by RSH of an announcement regarding a capital raising and placement of shares to continue the acceleration of the USA commercialisation strategy.

$6.5m capital raise from investors at 3% discount to last closing price. $5m from key cornerstone investor that recognises Respiri's potential for growth in the USA Remote Patient Monitoring market. Principal Wealth Group Pty Ltd, a Sydney based advisory firm, has committed up to $20m to fund future acquisitions o Respiri funded to anticipated Cash Flow break-even expected in 2H CY24.

The securities of Respiri Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of RSH, pending the release of an announcement regarding a capital raising and placement of shares to continue the acceleration of the USA commercialisation strategy.

The suspension of trading in the securities of Respiri Limited will be lifted immediately following the release by RSH of an announcement regarding an equity raising and a strategic acquisition.

Respiri US subsidiary, Respiri USA Inc., to acquire ACCESS, a US-based Remote Patient Monitoring and Chronic Care Management services provider and existing sales/marketing partner for wheezo® for up to USD$3 Million. Respiri is now the first Australian RPM Company in delivering complete, end-to-end turnkey RPM services to US Healthcare Organization customers with differentiating medical device intellectual property. The Acquisition increases Respiri RPM per patient monthly recurring revenues from USD$10-20 to USD$70-$100, highlighting significant revenue upside that will reduce projected monthly break-even patient volume from approximately 30K to 9K patients for the total merged entity. Recent appointed Head of US operations, Will Sigsbee, will lead ACCESS with their key personnel committing to remain. The Acquisition will be funded via a A$4.5 Million convertible note issue in conjunction with a A$2 Million share purchase plan offer.

The securities of Respiri Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of RSH, pending the release of an announcement regarding an equity raising and a strategic acquisition.

The suspension of trading in the securities of Respiri Limited will be lifted immediately following the release by RSH of an announcement regarding a capital raise.

The company releases a copy of its investor presentation.

The company releases a notification of proposed issue of securities.

$1.6 million (before costs) to be raised through a share placement of at $0.045 (4.5 cents) per fully paid ordinary share. The Placement will occur via one tranche and expects to be settled by Thursday 5th May 2022. Approximately 36 million new fully paid ordinary shares to be issued across the Placement. The Offer proceeds will be used to accelerate Respiri's commercialisation and roll-out strategy in the USA.

The company lodges its Quarterly Activities/Appendix 4C Cash Flow Report.

The securities of Respiri Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of RSH, pending the release of an announcement regarding a proposed capital raise.

The suspension of trading in the securities of Respiri Limited will be lifted immediately following the release by RSH of an announcement regarding a capital raising.

The company signed a Joint Development Agreement with Phenix Health, an Australian based health workflow designer for virtual healthcare settings. Under the terms of the JDA, Respiri will work to ensure that the wheezo eHealth SaaS monitoring platform is integrated into the Phenix proprietary telehealth platform, patient dashboards and asthma management plans. Phenix will we be responsible for providing patients already diagnosed with asthma the option of using wheezo to help monitor their condition and so providing healthcare beyond the clinic setting.

The Company is providing its loyal shareholders with an opportunity to participate in the SPP to raise up to $1million (before costs) by the issue of up to 18,181,819 SPP Shares, with the capacity to accept an additional $1 million (before costs) pursuant to the Oversubscription. Under the SPP Offer, each Eligible Shareholder may apply for up to $30,000 worth of new Shares at $0.055 per Share. Applications may be made in parcels of $1,000, $2,000, $5,000, $10,000, $15,000, $20,000, $25,000 and $30,000 worth of SPP Shares. Investors should note that the Company will only be accepting Applications under the SPP Offer from Eligible Shareholders that have not disposed of any of their shares between the re-commencement of trading following the Opening of the SPP Offer at 6pm on 9 April 2020 and the Closing of the SPP Offer on 1 May 2020.

The company's general meeting will be held on 26 May 2020 at 2pm (Melbourne time). Registration is from 1pm. The web address for the meeting is: https://web.lumiagm.com with meeting ID 385-292-319.

The company issues a prospectus for an offer to Eligible Shareholders to participate in a Share Purchase Plan by subscribing for up to $30,000 worth of new Shares at an at an offer price of $0.055 (5.5 cents) per Share to raise up to $1 million (before costs), with the capacity to accept up to an additional $1 million (before costs) pursuant to the Oversubscription. The prospectus is also for a separate offer to remain open for up to 3 months from the close of the SPP Offer, to subscribe for any SPP Shares not taken up pursuant to the SPP Offer to be issued at an offer price of $0.055 per Shortfall Share, being the price at which SPP Shares have been offered under the SPP Offer.

The company releases the following: a prospectus for a Share Purchase Plan (SPP) closing on 1 May 2020, and a notice of an Extraordinary General Meeting (EGM) to be held on 26 May 2020.

The company releases an Appendix 2A.

The company releases an updated notice of Proposed issue of Securities - RSH.

The company releases a notice of Proposed issue of Securities - RSH.

The company announces the successful completion of a share placement raising $2.0 million before costs. The company also announces a share purchase plan to raise up to a further $1 million (before costs). The company may, subject to shareholder demand, accept oversubscriptions under the SPP for an additional $1 million (before costs). The SPP offer to eligible shareholders provides the opportunity to purchase up to $30,000 of new Respiri shares under the SPP offer at $0.055 per share. The SPP is limited to shareholders with a registered address in Australia and New Zealand who were shareholders as at the record date of 25 March 2020. It is anticipated that the SPP offer will be open for three weeks from 10 April 2020 to 01 May 2020.

The securities of Respiri Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of RSH, pending the release of an announcement regarding the proposed capital raising.

The suspension of trading in the securities of Respiri Limited will be lifted immediately following the release by RSH of an announcement regarding a capital raising.

The company has successfully conducted a $3.4 million capital raising via a private placement to sophisticated and professional investors. The placement price is 10.0 cents per fully paid ordinary shares in the capital of the company. The fund raising has had broad support from a number of Respiri's long-term investors and was underpinned by leading family offices including the Smedley Family Office. The placement also includes $100,000 from the directors of the company.

The securities of Respiri Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of RSH, pending the release of an announcement regarding a capital raising.

The suspension of trading in the securities of Respiri Limited (the "Company") will be lifted immediately, following the announcement of a capital raising by the Company.

The company is pleased to announce that it will provide eligible shareholders with the opportunity to participate in a 1 for 2 renounceable entitlement offer of new RSH shares at an issue price of $0.03 per New Share to raise up to $4.3M. The Entitlement Offer has been fully underwritten by the Company's mandated brokers Patersons Securities Limited.

The securities of Respiri Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company.

name changed from iSonea Limited